Senores Pharmaceuticals Limited
Senores Pharmaceuticals Limited (SENORES) financial statements and selected valuation metrics from NSE/BSE exchange filings through 30 June 2026.
Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals
senorespharma.com(opens the company website in a new tab)Key metrics
Price as of 2026-09-02
Sign in for full ratios and TTM. Learn about these metrics →
Share price
NSE closing price from historical market data.
Loading price history…
Statement tables · Consolidated
Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.
Amounts in ₹ Cr · NSE preferred when both exchanges report the same period · tap + to expand rows
Quarterly results
Quarterly · ₹ Cr · tap + rows to expand
| Metric | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Jun 2026 |
|---|---|---|---|---|---|---|
| Sales | 103 Cr | 114 Cr | 138 Cr | 162 Cr | 175 Cr | 180 Cr |
| Operating expenses (approx.) | 77 Cr | 95 Cr | 104 Cr | 112 Cr | 121 Cr | 126 Cr |
| EBITDA | 26 Cr | 19 Cr | 34 Cr | 50 Cr | 54 Cr | 54 Cr |
| OPM % | 24.9% | 17.0% | 24.8% | 30.6% | 30.9% | 29.8% |
| Other income | 5 Cr | 12 Cr | 3 Cr | 5 Cr | 4 Cr | 3 Cr |
| Interest | 6 Cr | 5 Cr | 5 Cr | 6 Cr | 5 Cr | 7 Cr |
| Depreciation | 4 Cr | 5 Cr | 6 Cr | 8 Cr | 8 Cr | 10 Cr |
| Profit before tax | 20 Cr | 21 Cr | 26 Cr | 41 Cr | 45 Cr | 39 Cr |
| Tax % | 19.8% | 13.1% | 20.0% | 25.9% | 24.7% | 22.8% |
| Net profit | 16 Cr | 18 Cr | 21 Cr | 30 Cr | 34 Cr | 30 Cr |
| EPS (₹) | ₹5.04 | ₹3.81 | ₹4.60 | ₹6.54 | ₹7.29 | ₹6.61 |
Profit & loss (annual)
Annual · last column is TTM · ₹ Cr · tap + to expand
| Metric | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|
| Sales | 398 Cr | 633 Cr | Sign in for TTM |
| Operating expenses (approx.) | 309 Cr | 464 Cr | Sign in for TTM |
| EBITDA | 90 Cr | 168 Cr | Sign in for TTM |
| OPM % | 22.5% | 26.6% | Sign in for TTM |
| Other income | 19 Cr | 47 Cr | Sign in for TTM |
| Interest | 22 Cr | 25 Cr | Sign in for TTM |
| Depreciation | 17 Cr | 31 Cr | Sign in for TTM |
| Profit before tax | 71 Cr | 159 Cr | Sign in for TTM |
| Tax % | 17.3% | 23.6% | Sign in for TTM |
| Net profit | 58 Cr | 122 Cr | Sign in for TTM |
| EPS (₹) | ₹16.12 | ₹26.39 | Sign in for TTM |
| Dividend payout % | 0.0% | 0.0% | Sign in for TTM |
Trailing twelve months totals and margin rows
Balance sheet
Annual · ₹ Cr · tap + rows to expand
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Equity capital | 46 Cr | 46 Cr |
| Reserves | 740 Cr | 888 Cr |
| Borrowings | 305 Cr | 327 Cr |
| Other liabilities | 110 Cr | 312 Cr |
| Total liabilities | 1,227 Cr | 1,604 Cr |
| Fixed assets (net) | 199 Cr | 331 Cr |
| CWIP | 44 Cr | 17 Cr |
| Investments | 0.01 Cr | 29 Cr |
| Inventories | 57 Cr | 89 Cr |
| Trade receivables | 124 Cr | 325 Cr |
| Cash & bank | 105 Cr | 46 Cr |
| Other assets | 698 Cr | 766 Cr |
| Total assets | 1,227 Cr | 1,604 Cr |
Cash flows
Annual · ₹ Cr · tap + rows to expand · last column includes FCF
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Cash from operating activity | -46 Cr | 62 Cr |
| Cash from investing | -429 Cr | -121 Cr |
| Cash from financing | 573 Cr | -1 Cr |
| Net cash flow | 98 Cr | -60 Cr |
| Free cash flow (OCF − Capex) | -203 Cr | -178 Cr |
Ratios
Ratios as reported or derived per annual period.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| ROCE % | 8.2% | 14.3% |
| ROE % | 7.2% | 0.0% |
| Debtor days | 113 | 187 |
| Inventory days | 225 | 284 |
| Days payable | 267 | 748 |
| Cash conversion cycle | 71 | -276 |
| Debt / equity | 0.39 | 0.35 |
| Current ratio | 3.00 | 1.92 |
| Net debt / EBITDA | 2.22 | 1.67 |
Compare with peers
Loading peers…